je.st
news
Interim Data from Proof-of-Concept Study of Merck's Investigational...
2014-11-10 08:38:26| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: data
study
interim
investigational
Category:Biotechnology and Pharmaceuticals